浙江医药
(600216)
| 流通市值：134.72亿 | | | 总市值：134.73亿 |
| 流通股本：9.62亿 | | | 总股本：9.62亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,695,297,924.39 | 4,322,874,759.83 | 2,255,389,182.25 | 9,375,216,922.05 |
| 营业收入 | 6,695,297,924.39 | 4,322,874,759.83 | 2,255,389,182.25 | 9,375,216,922.05 |
| 二、营业总成本 | 5,638,082,321.04 | 3,511,652,540.63 | 1,778,067,510.03 | 7,934,024,498.03 |
| 营业成本 | 4,184,975,452.75 | 2,601,595,840 | 1,276,624,488.31 | 5,406,540,720.17 |
| 税金及附加 | 65,753,990.71 | 39,771,426.47 | 22,867,656.49 | 96,537,176.84 |
| 销售费用 | 673,694,784.67 | 451,716,144.12 | 240,680,661.64 | 1,100,198,245.79 |
| 管理费用 | 333,640,913.23 | 209,433,285.89 | 101,147,264.96 | 586,352,955.75 |
| 研发费用 | 473,281,101.15 | 313,508,800.49 | 177,463,871 | 749,353,351.93 |
| 财务费用 | -93,263,921.47 | -104,372,956.34 | -40,716,432.37 | -4,957,952.45 |
| 其中:利息费用 | 18,476,829.67 | 12,032,068.08 | 5,759,353.46 | 26,401,130.05 |
| 其中:利息收入 | 21,172,025.23 | 15,254,985.23 | 8,042,734.74 | 22,506,017.29 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 21,364,508.75 | 1,276,670.78 | -2,145,344.99 | -21,534,114.35 |
| 加:投资收益 | 5,364,932.36 | -3,372,533.17 | 8,080,460.07 | -8,069,379.83 |
| 资产处置收益 | -7,551.84 | 178,709.95 | -899,293.52 | 3,090,739.73 |
| 资产减值损失(新) | -94,216,487.48 | -79,707,143.85 | -40,520,287.07 | -263,898,853.78 |
| 信用减值损失(新) | 7,131,143.43 | 5,305,840.36 | 1,014,082.9 | 343,806.26 |
| 其他收益 | 51,442,194.83 | 27,095,821.76 | 11,399,069.04 | 71,985,823.25 |
| 四、营业利润 | 1,048,294,343.4 | 761,999,585.03 | 454,250,358.65 | 1,223,110,445.3 |
| 加:营业外收入 | 3,963,418.9 | 653,595.98 | 339,558.6 | 3,293,512.09 |
| 减:营业外支出 | 5,951,175 | 3,771,760.85 | 807,455.8 | 14,121,769.98 |
| 五、利润总额 | 1,046,306,587.3 | 758,881,420.16 | 453,782,461.45 | 1,212,282,187.41 |
| 减:所得税费用 | 179,574,974.36 | 134,310,263.92 | 68,530,046.15 | 192,030,677.23 |
| 六、净利润 | 866,731,612.94 | 624,571,156.24 | 385,252,415.3 | 1,020,251,510.18 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 866,731,612.94 | 624,571,156.24 | 385,252,415.3 | 1,020,251,510.18 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 933,147,906.73 | 673,306,732.88 | 409,085,292.06 | 1,160,510,670.41 |
| 少数股东损益 | -66,416,293.79 | -48,735,576.64 | -23,832,876.76 | -140,259,160.23 |
| 扣除非经常损益后的净利润 | 890,908,849.74 | 665,480,908.03 | 402,222,697.47 | 1,160,134,311.05 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.97 | 0.7 | 0.43 | 1.21 |
| (二)稀释每股收益 | 0.97 | 0.7 | 0.43 | 1.21 |
| 八、其他综合收益 | 23,198,143.35 | 28,286,096.28 | 9,122,458.68 | -7,635,393.08 |
| 归属于母公司股东的其他综合收益 | 21,758,147.23 | 26,563,637.2 | 8,566,985.02 | -7,129,981.59 |
| 九、综合收益总额 | 889,929,756.29 | 652,857,252.52 | 394,374,873.98 | 1,012,616,117.1 |
| 归属于母公司股东的综合收益总额 | 954,906,053.96 | 699,870,370.08 | 417,652,277.08 | 1,153,380,688.82 |
| 归属于少数股东的综合收益总额 | -64,976,297.67 | -47,013,117.56 | -23,277,403.1 | -140,764,571.72 |
| 公告日期 | 2025-10-28 | 2025-08-26 | 2025-04-24 | 2025-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |